<SEC-DOCUMENT>0001564590-18-011864.txt : 20180508
<SEC-HEADER>0001564590-18-011864.hdr.sgml : 20180508
<ACCEPTANCE-DATETIME>20180508163019
ACCESSION NUMBER:		0001564590-18-011864
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180508
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180508
DATE AS OF CHANGE:		20180508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		18815069

	BUSINESS ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>abio-8k_20180508.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
abio-8k_20180508.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="text-align:justify;border-top:Solid 0.75pt #000000;padding-top:0pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, D.C. 20549 </p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8-K </p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported):<font style="color:#000000;font-size:12pt;"> </font><font style="color:#000000;">May 8, 2018 (May 8, 2018)</font></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as Specified in Its Charter)</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">000-22873</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">36-3855489</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Incorporation)</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission File Number)</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11080 CirclePoint Road, Suite 140, Westminster, CO</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">80020</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices)</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s Telephone Number, Including Area Code: (720) 940-2200</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former Name or Former Address, if Changed Since Last Report) </p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </p></td></tr></table></div>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="text-align:justify;margin-top:4pt;border-top:Solid 0.75pt #000000;padding-top:0pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Section&#160;2 &#8212; Financial Information</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.02.</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations and Financial Condition.</p></td>
</tr>
</table></div>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 8, 2018, ARCA biopharma, Inc. (&#8220;ARCA&#8221;) issued a press release reporting financial results for the quarter ended March&#160;31,&#160;2018.&nbsp;&nbsp;</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The press release is attached hereto as Exhibit&#160;99.1, which is furnished under Item 2.02 of this report and shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.</p>
<p style="margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Section 9 &#8212; Financial Statements and Exhibits </p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01. Financial Statements and Exhibits. </p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Exhibits. </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:78.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="text-align:center;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Number</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="abio-ex991_6.htm"><font style="text-decoration:underline;">Press Release titled &#8220;ARCA biopharma Announces First Quarter 2018 Financial Results and Provides Corporate Update&#8221; dated May 8, 2018</font>.</a></p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:62.25%;"></td>
<td style="width:4.17%;"></td>
<td style="width:5.5%;"></td>
<td style="width:28.08%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: May 8, 2018</p></td>
<td colspan="3" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Registrant)</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Brian L. Selby</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brian L. Selby</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President, Finance and Chief Accounting Officer</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>abio-ex991_6.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
abio-ex991_6.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><img src="g201805042218262161073.jpg" title="" alt="" style="width:203px;height:69px;"></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:48.89%;"><br />&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">ARCA Biopharma announces first quarter 2018 financial results AND Provides Corporate update</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">-------------------------------------------------------------------------------------------------- </p>
<p style="text-align:center;margin-bottom:16pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">End-of-Phase 2 Meeting with the U.S. FDA Scheduled for the Last Week of June to Review Gencaro Phase 2 Data and Future Development Plan</p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Westminster, CO, May 8, 2018<font style="font-style:normal;"> &#8211; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended March 31, 2018.</font></p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;The first quarter of this year saw an important milestone for the Gencaro development program with the reporting of top-line Phase 2B results for the GENETIC-AF clinical trial evaluating Gencaro as potentially the first genetically-targeted treatment for atrial fibrillation,&#8221; commented Dr. Michael Bristow, ARCA&#8217;s President and Chief Executive Officer.&nbsp;&nbsp;&#8220;Our End-of-Phase 2 meeting with the U.S. FDA is scheduled for the last week of June when we will review the data and potential future development plans for Gencaro.&#8221; </p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pipeline Update</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Gencaro</font><font style="font-weight:normal;"> (bucindolol hydrochloride) - a pharmacologically unique beta-blocker and mild vasodilator being developed for the potential treatment of patients with atrial fibrillation (AF) and chronic heart failure with reduced left ventricular ejection fraction (HFrEF).</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9642;</font></p></td>
<td valign="top">
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;">ARCA reported (February 26, 2018) top-line data for GENETIC-AF Phase 2B clinical trial evaluating Gencaro as potential treatment for atrial fibrillation.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;font-family:Courier New;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Courier New;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><a name="_Hlk511741718"></a><font style="font-family:Times New Roman;">In all patients, Gencaro demonstrated a similar treatment benefit compared to the active control, metoprolol succinate (TOPROL-XL) (143 total events, hazard ratio of 1.01 (95% confidence interval: 0.71, 1.42). In U.S. patients (127 of 267 total patients), a trend for potential benefit in favor of Gencaro (approximately 30% risk reduction over TOPROL-XL), was observed for the primary endpoint of time to recurrence of AF<a name="_Hlk511741718"></a> (73 events, hazard ratio 0.70, [0.41, 1.19]). Safety data indicated that Gencaro was generally safe and well-tolerated in the AF/heart failure (HF) population investigated with a safety profile similar to TOPROL-XL.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;font-family:Courier New;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Courier New;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><a name="_Hlk511728866"></a><font style="font-family:Times New Roman;">Further analysis of the GENETIC-AF trial data indicates the regional heterogeneity observed may be attributable to differences in baseline characteristics of enrolled patients, specifically differences in the underlying pathophysiology leading to the development of AF.</font></p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9642;</font></p></td>
<td valign="top">
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-family:Times New Roman;">An End-of-Phase 2 meeting is scheduled with the U.S.&nbsp;&nbsp;Food and Drug Administration (FDA) for the last week of June to review the GENETIC-AF data and potential future Gencaro development plans.&nbsp;&nbsp;Within 30 days following the meeting, the FDA will provide written minutes of the meeting to confirm the discussions.&nbsp;&nbsp;ARCA plans to provide an update </font><font style="font-family:Times New Roman;">on Gencaro </font><font style="font-family:Times New Roman;">potential </font><font style="font-family:Times New Roman;">future development plans subsequent to rece</font><font style="font-family:Times New Roman;">iving the FDA meeting minutes.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9642;</font></p></td>
<td valign="top">
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;">In April 2018, Medtronic, Inc. and ARCA agreed to extend their current U.S., Canadian and European Clinical Trial Collaboration Agreement for one additional year.</font></p></td></tr></table></div>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">AB171</font><font style="font-weight:normal;"> &#8211; a thiol-substituted isosorbide mononitrate being developed as a potential genetically-targeted treatment for peripheral arterial disease (PAD) and for heart failure (HF).</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';">&#9642;</font></p></td>
<td valign="top">
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;">Chemistry, manufacturing and controls (CMC) activities initiated in first quarter of 2018.</font></p></td></tr></table></div>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">First Quarter 2018 Summary Financial Results</p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and marketable securities <font style="font-weight:normal;">totaled $12.1 million as of March 31, 2018, compared to $11.8 million as of December 31, 2017. ARCA believes that its current cash, cash equivalents and marketable securities will be sufficient to fund its operations, at its projected cost structure, through the end of 2018. </font></p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Research and development (R&amp;D) expenses<font style="font-weight:normal;"> for the quarter ended March 31, 2018 totaled $1.7 million compared to $3.2 million for the corresponding period of 2017.&nbsp;&nbsp;The $1.5 million decrease in research and development expenses in the first quarter of 2018 as compared to the first quarter 2017 was primarily due to decreased clinical expenses following the completion of the GENETIC-AF clinical trial.&nbsp;&nbsp;The Company expects R&amp;D expenses in 2018 to be lower than 2017 as the GENETIC-AF clinical trial has been completed. </font></p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">General and administrative (G&amp;A) expenses<font style="font-weight:normal;"> for the quarter ended March 31, 2018 were $1.1&#160;million, similar to the $1.1 million in the first quarter of 2017.&nbsp;&nbsp;ARCA expects G&amp;A expenses in 2018 to be consistent with those in 2017 as it maintains administrative activities to support ongoing operations. </font></p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses<font style="font-weight:normal;"> for the quarter ended March 31, 2018 were $2.8 million compared to $4.4 million for the first quarter of 2017.&nbsp;&nbsp;The decrease in total operating expenses for the first quarter of 2018 was primarily due to the decrease in R&amp;D expense due to the completion of the GENETIC-AF clinical trial. </font></p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net loss<font style="font-weight:normal;"> was $2.7 million, or $0.20 per share, for the first quarter of 2018 compared to $4.3 million, or $0.48 per share, for the first quarter of 2017. </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About ARCA biopharma</font></p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA&#8217;s lead product candidate, Gencaro<sup style="font-size:85%; vertical-align:top">TM</sup> (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the potential treatment of patients with atrial fibrillation (AF) and chronic heart failure with reduced left ventricular ejection fraction (HFrEF) which recently completed a Phase 2B clinical trial. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted AF prevention treatment. ARCA has a collaboration with Medtronic, Inc. for support of the GENETIC-AF trial. The Gencaro development program has been granted Fast Track designation by FDA. ARCA also plans to develop AB171, a thiol-substituted isosorbide mononitrate, as a potential genetically-targeted treatment for peripheral arterial disease (PAD) and for heart failure (HF). For more information, please visit <font style="text-decoration:underline;">www.arcabio.com</font>. </p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Safe Harbor Statement</p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">This press release contains "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the ability of ARCA&#8217;s financial resources to support its operations through the end of 2018, potential future development plans for Gencaro, the expected features and characteristics of Gencaro or AB171, including the potential for genetic variations to predict individual patient response to Gencaro, Gencaro&#8217;s potential to treat AF, AB171&#8217;s potential to treat HF, future treatment options for patients with AF, and the potential for Gencaro to be the first genetically-targeted AF prevention treatment<font style="font-size:11.5pt;">. </font>Such statements are based on management's current expectations and involve risks and uncertainties.&nbsp;&nbsp;Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: ARCA&#8217;s financial resources and whether they will be sufficient to meet its business objectives and operational requirements; ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or to otherwise continue operations in the future; results of earlier clinical trials may not be confirmed in future trials; the protection and market exclusivity provided by ARCA&#8217;s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes.&nbsp;&nbsp;These and other factors are identified and described in more detail in ARCA&#8217;s filings with the Securities and Exchange Commission, including without limitation ARCA&#8217;s annual report on Form 10-K for the year ended December&#160;31, 2017, and subsequent filings. ARCA disclaims any intent or obligation to update these forward-looking statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Investor &amp; Media Contact:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derek Cole</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">720.940.2163</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">derek.cole@arcabio.com</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">###</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Tables follow)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA BIOPHARMA, INC.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BALANCE SHEET DATA </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(unaudited)</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;"><font style="margin-left:36pt;"></font>&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;"><font style="margin-left:36pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>  <font style="text-decoration:underline;font-size:12pt;">March 31, 2018</font><font style="text-decoration:underline;font-size:12pt;margin-left:36pt;"></font><font style="font-size:12pt;margin-left:36pt;"></font><font style="text-decoration:underline;font-size:12pt;">December 31, 2017</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:78.5%;">
<tr>
<td style="width:38.5%;"></td>
<td style="width:20.61%;"></td>
<td style="width:19.39%;"></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents &amp; marketable securities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$12,096</p></td>
<td valign="top"  BGCOLOR="#FFFFFF">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$11,752</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Working capital</p></td>
<td valign="top"  BGCOLOR="#CFF0FC">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$11,008</p></td>
<td valign="top"  BGCOLOR="#CFF0FC">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$10,229</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="top"  BGCOLOR="#FFFFFF">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$12,788</p></td>
<td valign="top"  BGCOLOR="#FFFFFF">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$12,365</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="top"  BGCOLOR="#CFF0FC">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$11,054</p></td>
<td valign="top"  BGCOLOR="#CFF0FC">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$10,275</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA BIOPHARMA, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(unaudited)</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39%;">
<p style="text-align:center;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39%;">
<p style="text-align:center;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share</p>
<p style="text-align:center;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and per share amounts)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs and expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,720</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,246</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,053</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,135</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total costs and expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,773</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,381</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,773</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,381</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60%; border-bottom:double 2.5pt transparent;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,735</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:double 2.5pt transparent;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,338</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in unrealized loss on marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60%; border-bottom:double 2.5pt transparent;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,733</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:double 2.5pt transparent;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,328</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.20</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.48</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares outstanding:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,620,710</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;white-space:nowrap;">
<p style="text-align:right;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,094,276</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;line-height:18pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g201805042218262161073.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201805042218262161073.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "> =$# 2(  A$! Q$!_\0
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MI_X* >/5\*^#=1U>RFU HT>C^#8#8B!00ID>Y!,R1Y9=[23",9&<"O:?A/\
M\&\WC_XJ,=>^+/Q)M](U;4#'<36]K&^LWK[AEUGN)'15E4\93SE)R0Q'6/:-
M[(OV=MV?I)?_ +;'P;TJ;R[KXM?#.VDR1ME\46*-D=1@RUL>%_VE?AWXXNUM
M]%\>^"]8N&SB.RUNVN'..O".3W'YU\;Q?\&Y/P16,!O$_P 46;')_M*Q'/\
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M>6[V]Q"=KHXZ>GU!'((X(.15?1-+R!7M/PN;3O'NFV_AWQ!^[EC&S3+\?ZR
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M.@I=?M+>/M2X\RS\,K:J>^);J)C_ .B17['"JI;$U'J%%%%:&84444 %%%%
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MVEW&KI<0Z-"7#RZ9 ZI' 2%<Q[HE4,P4@,[''.*^\%_X. ?B B@+^SQJ"@<
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M $__ *4&OSH\*V,>J>)]-M9EW0W%U%%( <95G //T-?HO_P<G_\ )>/AO_V
M)_\ TH-?G=X%_P"1WT?_ *_H/_1BURRW.J.Q^WOBS_@@5^SWX@TN6"RTWQ1H
M4SKA;FSUJ222,^H$PD4_B*_+W_@HQ_P3A\2?L!?$"WBN+AM=\'ZTS?V1K2P^
M7O(Y,$R\A)E'.,X<?,.C*O\ 0Q7F_P"UE^S%X?\ VOO@1KG@7Q%&JVNJ1;K6
M[$>Z33;I<F*XCY'S(W.,C<I92=K&MI4TUH8QJ-/4_G8_9L_: U[]ESXV^'_'
M7AN15U/0;CS1&_\ J[J(@K+"_P#LNA93W&<C! (_HR_9G_:(\._M4_!70_''
MA>?S=-UJ#<T3$>;9S#B2"0=G1@5/8X!&003_ #?_ !Q^#.O?L\_%K7O!?B:U
M^QZUX?NFMKA.JOT*2(>Z.A5U/=6!KZA_X(W_ /!0IOV/?C7_ ,(SXDOFC^'?
MC2=(KUI7/EZ1=8VQW8'15/RI(>,H%8D^6 <Z<K.S-*D;JZ/W<HI$.Y0>N>:6
MN@YS@_VI/#TGB_\ 9H^(FDPC=+JGAC4K1!ZF2UE0?J:_F3K^J:6-98V5E5E8
M$$$9!%?S0_M?_!";]F_]I_QSX)FA:WCT#5YHK568,6M6/F6SY']Z%XV]?FYP
M:QK&U+L?:G_!MOKD=O\ M)?$#33_ *Z[\-)<J/\ 9BNHE/ZRK7[&5_/E_P $
M??C?#\"O^"@/@6[O)9HM-\0S/X>NO+_B^UKY<.[D?*+CR&/H%)Y(Q7]!HZ55
M+8FIN%%%%:&84444 %%%% !10&R:* "@MBBOES_@L!^U.W[+7[%/B&XL;G[/
MXB\6C_A'])*EEDC>=6$TJE2"K1P"5E;H'\OUP4W97&E=V/R*_P""DG[2,W[:
M'[<GB#6--BNM9T33YAHVBP6@9GGLK8MEH_E)'F-YLN=IP).1Q7V/X:_X+P^-
M/"'AVPTG3?V<;RTT_2[:.TM8$U&YVPQ1J$11_HO0* /PK(_X-Q_V:/[3\3^,
MOBQJ%ONBTV,>'M(:2)64RR;9;F12>59$$* CJL\@]17ZT5E&+>IK*26EC\N_
M^(@/X@_]&\ZA_P"#*Y_^1*^7?^"E_P"W1KG[>/AWP[=:Q\(=0\%WGA.68KJA
MN)IU>"8*&B<- @ WHA!)X.0!\QK]YJYOXP?#+3_C3\*/$GA'51_Q+O$VFW&F
M7!"AF1)8V0LN>-RYR#V(!JG!M;DJ:3V/Y?8)Y+:=)(W:.2-@R,IPRD<@@^HK
M^D3]@7]HV/\ :L_9'\%>-&D634+ZP6WU0!@62]A)BGR!]W<Z%P#SM=3WK^=7
MXE_#_4OA/\1-=\+ZQ"8-4\/7\^G7:'^&6)RC8]LKP>XK])O^#<7]I/\ L[Q)
MXT^$]]<;8=10>(M)0J !,@6&Y7=U)9/(8#H!$Y[\YTW9FE175S]9J***Z#G"
MBBB@#\L[6=K>965BK Y!'4&M[3-1:27<S,S,<L2<DFL_QGX<D\(>+]4TJ966
M33;N6V;(Z[&*Y_'&:KV-WY+5_GC6ISHU'"6CB[->:T/WC2<5);,]#T35!@5[
M7\.+C3?A=IT&N:VOVC5)E#Z;IP;#!2.)I/[H/\.>>X!X(^?_  OK\.@O'=21
MQW-RO,$4@W1H>SNO1L=0IX/\65^5MJ/Q9/JM[)<74\EQ<3,7DDD;<SD]237V
M7#^>0P+5>RE47PWU4?[S75KHMD]7?8\3'8-UO<VCU[OR].Y[9+X^U/XG>)+6
M.XF#/<2K%#"GRQQ;FQP/QZG)P.O%>I?%3XG#P6UOIFFM&ETJAG. 1"G9<>I]
M^WU%>#_!'Q!;Z/K=UKMX-UKH-NTX4GB29ODB3ZECGVVD]JS]0\<7&NZI/>74
MADN+ES([>Y]/8= *_2<#Q=6PN73K<[=?$2^*^JA'2]_.3:7^%^1\]6RN-2NH
MV]R"V\WT^2U^9]'>-_$MOX6\%V^L:;;VMK=:H8\3)"H?#*7YXYX&.?6J>M^)
M8?B1\'[RZCQ]KL5$DR _<9.6./0KDC\NQKS;XB>.#=?"'P8BM\LJ3EQ[Q,(Q
M_6L+X6_%9/!WBA1=,3I>H+]FO5)XV-QNQZKG/TR.]?2XWC*'U_ZI5E:C5IQ3
M[1<X*7-\G+7R]$<%+*9>Q]K%>_&3:\[.UOPT.A\)?'*X\(H;.\C74M(E!22W
MD.2JG@[2>W^R>#[9S7'?%?1K73U75M'F^UZ%?.1$W\=K)U,,@ZAASC/4#()Y
MKG?&[/X:\0WVGR-N:SF>+=C&\ X##V(P1[&N?@\>7&A22^7Y<UO<+Y=Q;RC=
M%<)Z,/U!&"IP000#7Y;F7$<YT7@,?JH-J+WE![-><>\>FZVL_H\/EZ4O;4>N
MZZ/_ (/G]YG:WJ6[=7+ZAJ3Q"39(R^8-K8.-P]#[5?\ $=W#O,MNS&WD)VJ[
M9>/_ &6]?8XP?8Y YNYG\UZ_-,34E*IN?24:=E<]4_8E;/[3/A[_ ';K_P!)
MI:^^*^&_V!?#DVL?'N*]0?N=)LIIY&[?,/* ^IWY_ U]R#I7]5^"-&4.'YRD
MM)59->G+!?FF?F_&4D\<DND5^;?ZA1103@5^P'R8C?=K\$/^"JWQ^U#]M_\
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M)J6AV;1^ /&CR7FD%%'EZ?-G,UG[!"0R<?<=1DE&-8U(]4;4Y=#[;_X(4?\
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MFZC<6%AK,VB7=^]W$CLB7,;Y6##@!Q\KJ P&6ZG]%.M&*]"2N8Q=C\'?B/\
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M'CG!KI=M &*N,;$2E?H0WMA!J5G-;W$,5Q;W"&.6*1 R2*1@JP/!!'!!ZU\
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MQU;P$*9M3\+7)NBN. );8HIQ_>96/)R2:_6;&:,4>SMLP]I?='Y]_P##SO\
M::_Z-*\4?]_;K_Y'HK]!,457*^XN9=@HHHJB VT=*** "BBB@ HHHH *,444
M &WFBBB@ HHHH ***#TH ,XK/M_%6F7>O3:5#J%E+J=O&)I;1)E::)"<;F3.
M0,D<D=Z^;?V_M>\4^!!9W5CXSOK73]9D,,>DVZ"W:)4C7>WFH0[J6/(;IO Z
M5O?\$]?A@WASX97?B2ZC;[=XDGS&SCYA!&2 <GGYG+GW 4UGS^]RFGL_=YCZ
M$HHHK0S#- .:1N17QY\'?%WQAN?VFK>WU1O$#0->$:E;W"/]AAM\G<R@_(H
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MRNKG/*-G8GU[Q#I_A?3)+S5+ZSTVSC(#SW4RPQ(2<#+,0!DG%1^'/%.E^,;
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M9_ZZ#WJO:/FL+V:Y;W/KRBBLGQOXWTOX=^&;K6-8NX[.PLUW22/W]% ZEB>
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:0@,",CUJWLQ2T4 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
